Φορτώνει......
The Benefit to Risk Balance of Combining Infliximab with Azathioprine Varies With Age: A Markov Model
BACKGROUND & AIMS: Combination therapy with infliximab and azathioprine has demonstrated benefit over monotherapy for moderate-to-severe Crohn’s Disease. Clinical trials and models have not accounted for age-specific risks associated with these therapies, including the risk of immunosuppression-...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Clin Gastroenterol Hepatol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2014
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4324381/ https://ncbi.nlm.nih.gov/pubmed/25117775 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2014.07.058 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|